title: Yeast retrotransposon particles as antigen delivery systems.
abstract: The development of technologies to produce recombinant proteins for use in the pharmaceutical industry has made substantial advances, in particular in the area of generating antigens containing multiple copies of important immunological regions. One such antigen-carrier system is based on the ability of a protein encoded by the yeast retrotransposon, Ty, to self-assemble into virus-like particles. Ty-fusion proteins retain this ability to form particles, and a range of hybrid VLPs carrying a variety of heterologous antigens have been produced and shown to induce potent immune responses. In particular, hybrid VLPs carrying the core protein p24 of HIV (p24-VLPs) have been shown to induce antibody and T-cell proliferative responses in both experimental animals and human volunteers, and immunization of rabbits with VLPs carrying the principal neutralizing determinant of HIV (V3-VLPs) resulted in the induction of neutralizing antibody responses and T-cell proliferation. Further studies with V3-VLPs have shown that this particulate antigen stimulates enhanced V3-specific lymphoproliferative responses as compared to whole recombinant gp120 or to V3 peptide conjugated to albumin. The V3-VLPs also induce potent CTL responses following immunization of mice in the absence of adjuvant. These responses are MHC class I restricted and are mediated by CD8-positive cells. These observations therefore demonstrate that hybrid Ty-VLPs induce both humoral and cellular immune responses against HIV and suggest that these immunogens may be important in combatting AIDS and other infections.
authors.affiliation: British Bio-technology Ltd., Oxford, United Kingdom.
authors.forename: A J
authors.initials: AJ
authors.lastname: Kingsman
authors.forename: N R
authors.initials: NR
authors.lastname: Burns
authors.forename: G T
authors.initials: GT
authors.lastname: Layton
authors.forename: S E
authors.initials: SE
authors.lastname: Adams
mesh_terms: D016915:AIDS Vaccines / Q000737:chemistry* / Q000276:immunology; D000818:Animals; D003602:Cytotoxicity, Immunologic; D005656:Fungal Proteins / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000276:immunology; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D018626:Retroelements / Q000276:immunology*; D012441:Saccharomyces cerevisiae / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014614:Vaccines, Synthetic / Q000737:chemistry* / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D005656:Fungal Proteins; D015699:HIV Envelope Protein gp120; D018626:Retroelements; D014614:Vaccines, Synthetic; C094737:p1 protein, yeast